Benitec's unique technology explained

DNA-directed RNA Interference (ddRNAi) is Benitec's unique RNAi platform for silencing unwanted genes. Our approach has distinct advantages over other methods of gene silencing such as siRNA, anti-sense and zinc finger nucleases. The following explains these differences. 

Benitec's patents cover the use of RNAi resulting from the introduction of a DNA construct to the target human cell nucleus in vivo, to effect long-lasting genetic silencing. To explain how ddRNAi is different, let’s first look at the other major approach to RNAi, small interfering, or siRNA.

Gene silencing by siRNA

In siRNA, double stranded (ds)RNA molecules are synthesized in a laboratory and introduced to the cell. The siRNA is designed to cleave the mRNA of the target gene, and so prevent production of the specific target protein. Delivering the siRNA molecule to the target organ or tissue in a way that maintains its activity and efficacy has proven to the most difficult aspect of siRNA-based therapeutics.

According to a review of drug delivery mechanisms, (Rao, Vorhies, Senzer et al)1 siRNA has a number of limitations:

Gene silencing by ddRNAi


Benitec Biopharma’s patented approach to gene silencing overcomes most of the challenges of siRNA-based methods, because it utilizes a DNA-based approach, called DNA-directed RNAi (ddRNAi). The difference lies in the method of introducing siRNA into the cell: ddRNAi causes the cell to produce siRNA itself, rather than introducing synthetic siRNA. ddRNAi achieves this by producing a precursor molecule called short hairpin RNA (shRNA) in the nucleus, which enters the cytoplasm and is processed to siRNA by the cell’s own machinery. The specific shRNA is coded for in the nucleus as a result of transfecting the cell with a DNA-based construct, hence the concept of RNAi directed by DNA.

ddRNAi introduces a DNA sequence directly into the cell’s nucleus, and to do that, a range of well-characterized gene therapy vectors, viral and non-viral, like lentivirus, adenovirus, AAV or modified polyethylenimine can be used. The DNA sequence codes for specific shRNAs which are processed to siRNAs and complete the RNAi cycle in the cytoplasm. Herein lies another major difference: because of the delivery mechanism and site, only a minute dose (perhaps as few as 5 copies) of the DNA construct is needed, yet the genetic change is long-lasting, because the shRNA continues to be expressed for long periods, potentially up to years from the integrated DNA construct (Sci Trans Med 2010).

Due to the low dose and short term administration (potentially as little as one dose) many of the drawbacks of siRNA methods, including toxicity, immune activation and unwanted gene effects (off-target effects) are overcome. Thus ddRNAi promises to deliver long lasting, relatively safe treatments (or potentially cures) for many human genetic conditions.

ddRNAi can also be used to target multiple genes or multiple parts of one gene, so more complex conditions can be treated with tiny doses, without the side-effects of high-dose, long term administration.

A major benefit for researchers and biopharma companies worldwide is that ddRNAi is a globally patented platform technology, rather than a proprietary gene specific technology or delivery mechanism. Thus, ddRNAi technology may be licensed from Benitec for therapeutic gene silencing of a wide range range of disease-associated genes in humans. 


1 Advanced Drug Delivery Reviews 2009
siRNA vs. shRNA: Similarities and differences. 
Rao DD, Vorhies JS, Senzer N, Nemunaitis J.
Advanced Drug Delivery Reviews 2009; 61: 746–759.